Reversal of cirrhosis in a patient with primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Vallone
Thomas M
TM
Division of Gastroenterology and Hepatology, Tufts-New England Medical Center, Boston, Massachusetts 02190, USA. tvallone@tufts-nemc.or
Ditelberg
Jeremy
J
Kaplan
Marshall M
MM
D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D003078:Colchicine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D019693:Hepatitis, Autoimmune / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008105:Liver Cirrhosis, Biliary / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D013577:Syndrome; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D002756:Cholagogues and Choleretics; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D014580:Ursodeoxycholic Acid; D003078:Colchicine; D011241:Prednisone; D008727:Methotrexate